A large subgroup of patients with a similar gene expression profile to Ph+ ALL without the classic BCR-ABL fusion gene (i.e., Ph-like ALL) were reported in 2009 as having a high rate of relapse with conventional chemotherapeutic regimens (39). The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.